Stakeholders must alter their mindsets when it comes to early-phase design and interpreting regulatory guidance for CGT trials.
Amy Raymond, PhD, PMP
Advertisement
Senior Director, Therapeutic Strategy Lead, Rare Disease, Worldwide Clinical Trials
Articles by Amy Raymond, PhD, PMP
Advertisement
Latest Updated Articles
Evolving Tools and Perspectives for the Development of Cell and Gene TherapiesPublished: May 16th 2023 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Preparation Tips to Minimize Impact of Regulatory Inspections for IRT Systems
2
Reimagining Clinical Operations Through Artificial Intelligence
3
Integrating AI Across Legacy Clinical Trial Systems
4
Balancing Human Oversight and Automation in AI-Driven Trials
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
